Recursion Pharmaceuticals, Inc. stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideStrong
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWatch
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its Evidence strength.
Discovery Gap: Very high (74/100) · Gap confidence 63/100
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideStrong 63/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideModerate 58/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Evidence timeline
- Expected
Thu 25 Feb · expected 10-K
Last year filed 25 Feb 2026.
Thu 6 May · expected 10-Q
Last year filed 6 May 2026.
- Filed
Mon 2 Nov · 8-K
8-K · Items 2.02, 5.02 — Results of operations
Recursion reported positive Phase 2 REC-4881 data in FAP showing deep, durable polyp reductions across GI tract; REC-1245 early signals in endometrial cancer; Sanofi optioned first development candidate ($10M milestone); cash runway extended to 2029; Fred Hassan appointed Board Chair.
Recognition: Balanced 50 → Balanced 47Value: Balanced 61 → Strong 65Gap Very high · 54 → Very high · 74Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
Mon 2 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Recognition: Balanced 50 → Balanced 47Value: Balanced 61 → Strong 65Gap Very high · 54 → Very high · 74Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
Thu 15 Oct · 8-K
8-K · Items 1.01, 2.02, 8.01 — Material agreement
Recursion raised ~$200M via equity offering and announced Sanofi optioned first development candidate from collaboration ($10M milestone, $300M+ additional potential). REC-4881 Phase 1b/2 showed 87% polyp burden reduction; REC-1245 Phase 1 showed 91.7% disease control at higher doses.
Recognition: Balanced 47 → Watch 44Gap Medium · 17 → Very high · 65Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Mon 21 Sep · 8-K
8-K · Item 1.01 — Material agreement
Recursion amended its Tempus Master Agreement, reducing annual fees from $42M to $14M while extending term to six years and eliminating convenience termination. Simultaneously licensed its TxFM RNA model to Tempus for $12M over two years in oncology applications.
Recognition: Watch 42 → Balanced 48Value: Balanced 52 → Balanced 62More of the market is starting to notice.
The shares became cheaper on AIR's value read.
The price trend strengthened.
Wed 5 Aug · 10-Q
Quarterly report (10-Q), period ending 31 Jul 2026
Wed 5 Aug · 8-K
Thu 18 Jun · 8-K
Wed 6 May · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Wed 6 May · 8-K
Thu 30 Apr · 8-K
Wed 25 Mar · 8-K
Wed 25 Feb · 8-K
Wed 25 Feb · 10-K
Annual report (10-K), FY2025
Mon 12 Jan · 8-K
Mon 8 Dec · 8-K
Wed 26 Nov · 8-K
Wed 5 Nov · 8-K
Wed 5 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2025
Wed 29 Oct · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.